Cue Health Inc. (HLTH) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cue Health Inc. (HLTH) trades at $0.0434 with AI Score 44/100 (Grade C). Cue Health Inc. develops and commercializes diagnostic platforms for various healthcare needs. Market cap: $6.90M, Sector: Healthcare.
Price as of Jul 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for HLTH: HLTH does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates HLTH against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
HLTH: 1/3 scored disciplines lean bearish. Dominant signal: Jim Simons bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Cue Health Inc. (HLTH) Healthcare & Pipeline Overview
Cue Health Inc. is a healthcare technology company focused on developing and marketing its Cue Integrated Care platform, which offers rapid, point-of-care diagnostic testing solutions. The platform targets individuals, enterprises, healthcare providers, and public health agencies, positioning it within the evolving landscape of decentralized diagnostics.
What Is the Investment Thesis for HLTH?
Cue Health Inc. presents a high-risk, high-reward investment opportunity within the point-of-care diagnostics market. The company's Cue Integrated Care platform offers a potentially disruptive solution for rapid and accurate testing. However, with a market capitalization of $6.90M, a negative profit margin of -581.5%, and a negative gross margin of -97.9%, the company faces significant financial challenges. Future growth hinges on expanding the test menu beyond COVID-19, securing regulatory approvals for new tests, and achieving wider market adoption. The company's beta of 1.09 suggests its stock price is as volatile as the market. Investors should carefully consider the company's financial position, competitive landscape, and execution risks before investing. The company's success depends on its ability to innovate, commercialize new diagnostic tests, and achieve profitability.
Based on FMP financials and quantitative analysis
HLTH Key Highlights
- Market capitalization of $6.90M indicates a micro-cap company with high growth potential but also significant risk.
- Negative profit margin of -581.5% reflects substantial losses and the need for improved cost management and revenue generation.
- Negative gross margin of -97.9% suggests that the cost of goods sold exceeds revenue, indicating unsustainable pricing or high production costs.
- Beta of 1.09 indicates that the stock is slightly more volatile than the overall market.
- The company operates in the rapidly evolving point-of-care diagnostics market, driven by demand for faster and more convenient testing solutions.
Who Are HLTH's Competitors?
HLTH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ETAO ETAO International Co., Ltd. | $1.91 | -31.79% | $9.78M | 42 |
| FRTX Fresh Tracks Therapeutics, Inc. | $0.94 | -0.53% | $5.59M | 54 |
| KA Kineta, Inc. | $0.57 | -30.77% | $7.05M | 45 |
| LCI Lannett Company, Inc. | $0.69 | +0.00% | $7.38M | 39 |
| CRBKF Carebook Technologies Inc. | $0.03 | +0.00% | $6.84M | 64 |
| CMHSF Comprehensive Healthcare Systems, Inc. | $0.34 | +0.00% | $6.22M | 55 |
| CMPD CompuMed, Inc. | $6.64 | +9.25% | $8.56M | 60 |
| BBLN Babylon Holdings Limited | $0.55 | -13.99% | $14.1M | 56 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are HLTH's Key Strengths?
- Integrated platform with hardware and software components.
- Rapid and accurate diagnostic results at the point of care.
- Data and analytics capabilities for healthcare providers and patients.
- Existing COVID-19 testing kits provide a foundation for future growth.
What Are HLTH's Weaknesses?
- Negative profit and gross margins indicate financial instability.
- Limited test menu beyond COVID-19.
- Dependence on regulatory approvals for new tests.
- Intense competition in the point-of-care diagnostics market.
What Could Drive HLTH Stock Higher?
- Potential FDA approval for new diagnostic tests on the Cue platform, expanding its clinical utility.
- Expansion of strategic partnerships with healthcare providers and payers to increase market access.
- Continued development and commercialization of new features and capabilities for the Cue Integrated Care platform.
What Are the Key Risks for HLTH?
- Financial-distress signal — its Altman Z-Score of -6.50 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-90.3%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Regulatory hurdles and delays in obtaining approvals for new tests.
- Intense competition from established players in the diagnostics market.
- Financial instability due to negative profit and gross margins.
- Changes in healthcare policies and reimbursement rates affecting the adoption of point-of-care diagnostics.
What Are the Growth Opportunities for HLTH?
- Expansion of Test Menu: Cue Health has the opportunity to expand its test menu beyond COVID-19 to include other infectious diseases, women's health, and chronic conditions. The market for point-of-care diagnostics is projected to reach $43.7 billion by 2027, offering a significant opportunity for Cue Health to increase its revenue and market share. Success depends on the company's ability to develop and validate new tests, obtain regulatory approvals, and integrate them into its existing platform. Timeline: Ongoing.
- Strategic Partnerships: Cue Health can pursue strategic partnerships with healthcare providers, payers, and pharmaceutical companies to expand its market reach and accelerate adoption of its platform. Collaborations with large healthcare systems could provide access to a broader patient base and facilitate integration into existing clinical workflows. The potential impact of these partnerships is significant, as they can drive revenue growth and enhance the company's credibility. Timeline: Ongoing.
- Geographic Expansion: Cue Health can expand its geographic presence beyond the United States to target international markets with unmet diagnostic needs. Emerging markets, in particular, offer significant growth opportunities due to increasing healthcare spending and limited access to traditional laboratory testing. Successful geographic expansion requires adapting the company's platform to local regulatory requirements and establishing distribution networks. Timeline: 2027-2030.
- Direct-to-Consumer Marketing: Cue Health can leverage direct-to-consumer marketing strategies to increase awareness and adoption of its platform among individuals seeking convenient and accessible diagnostic testing. This includes online advertising, social media campaigns, and partnerships with telehealth providers. The direct-to-consumer market for diagnostics is growing rapidly, driven by increasing consumer awareness and demand for personalized healthcare solutions. Timeline: Ongoing.
- Integration with Telehealth Platforms: Cue Health can integrate its platform with telehealth platforms to provide remote patient monitoring and virtual care services. This integration would enable healthcare providers to remotely monitor patients' health status, diagnose conditions, and prescribe treatments. The telehealth market is experiencing rapid growth, driven by increasing adoption of virtual care and remote monitoring technologies. The global telehealth market is projected to reach $55.6 billion by 2027. Timeline: 2027-2028.
What Opportunities Does HLTH Have?
- Expansion of test menu to include other infectious diseases and chronic conditions.
- Strategic partnerships with healthcare providers, payers, and pharmaceutical companies.
- Geographic expansion to international markets.
- Integration with telehealth platforms for remote patient monitoring.
What Threats Does HLTH Face?
- Competition from established players in the diagnostics market.
- Regulatory hurdles and delays in obtaining approvals for new tests.
- Changes in healthcare policies and reimbursement rates.
- Potential for technological obsolescence.
What Are HLTH's Competitive Advantages?
- Proprietary Technology: The Cue Integrated Care platform is based on proprietary technology, providing a competitive advantage.
- Integrated System: The integrated hardware and software components of the Cue platform create a seamless user experience.
- Rapid and Accurate Results: The Cue platform delivers rapid and accurate diagnostic results at the point of care.
- Data and Analytics Capabilities: The Cue Data and Innovation Layer provides valuable insights for healthcare providers and patients.
What Does HLTH Do?
Cue Health Inc., established in 2010 and headquartered in San Diego, California, is a healthcare technology company dedicated to designing and developing a diagnostic platform for a range of diagnostic tests. The company's core offering is the Cue Integrated Care platform, a comprehensive system comprising both hardware and software components. This platform includes the Cue Health Monitoring System, which features the Cue Reader (a portable, reusable reader), the Cue Cartridge (a single-use test cartridge), and the Cue Wand (a sample collection wand). The Cue Data and Innovation Layer provides cloud-based data and analytics capabilities, while Cue Virtual Care Delivery Apps, including the Cue Health App and Cue Enterprise Dashboard, facilitate virtual care delivery. The company also offers Cue Ecosystem Integrations and Apps, enabling integration with third-party applications and sensors. Initially, Cue Health gained prominence through its COVID-19 testing kits designed for use with the Cue Health Monitoring System. These kits provided rapid, on-site testing capabilities, addressing a critical need during the pandemic. The company's focus extends beyond COVID-19, with plans to expand its platform to detect a variety of other infectious diseases and health conditions. Prior to December 2017, the company was known as Cue Inc.
What Products and Services Does HLTH Offer?
- Designs and develops a diagnostic platform for various diagnostic tests.
- Offers the Cue Integrated Care platform, comprising hardware and software components.
- Provides the Cue Health Monitoring System, including the Cue Reader, Cue Cartridge, and Cue Wand.
- Offers the Cue Data and Innovation Layer, a solution with cloud-based data and analytics capability.
- Provides Cue Virtual Care Delivery Apps, including Cue Health App and Cue Enterprise Dashboard.
- Offers Cue Ecosystem Integrations and Apps, allowing integrations with third-party applications and sensors.
- Provides COVID-19 testing kits for the Cue Health Monitoring System.
How Does HLTH Make Money?
- Sells the Cue Health Monitoring System, including the Cue Reader and Cue Cartridges.
- Generates revenue from the sale of COVID-19 testing kits.
- Offers data and analytics services through the Cue Data and Innovation Layer.
- Provides virtual care delivery applications through the Cue Health App and Cue Enterprise Dashboard.
What Industry Does HLTH Operate In?
Cue Health Inc. operates within the medical and healthcare information services industry, a sector experiencing rapid growth due to technological advancements and increasing demand for point-of-care diagnostics. The market is characterized by intense competition, with established players like Laboratory Corporation of America (LCI) and emerging companies vying for market share. The industry is driven by trends such as personalized medicine, remote patient monitoring, and the need for rapid and accurate diagnostic testing. Cue Health's success depends on its ability to differentiate its platform, secure regulatory approvals, and establish strategic partnerships within this competitive landscape.
Who Are HLTH's Key Customers?
- Individuals seeking convenient and accessible diagnostic testing.
- Enterprises looking to provide on-site testing for employees.
- Healthcare providers needing rapid and accurate diagnostic information.
- Payors seeking to improve patient outcomes and reduce healthcare costs.
- Public health agencies requiring rapid disease surveillance and response capabilities.
Net sellingInsider Activity
The most recent 12 insider filings for Cue Health Inc. break down as 11 sales and 1 purchases. On net that is roughly 15.1M shares disposed (about $21K), a signal worth weighing alongside the fundamentals.
FY2026 estForward Outlook
Wall Street analysts project Cue Health Inc. revenue of about $162.4M for fiscal 2026, with EPS near $-0.31.
F-Score 3/9Financial Health
Cue Health Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -6.50 places it in the distress zone, a signal of elevated financial risk.
ROE -90%Key Financial Metrics
Return on equity for Cue Health Inc. stands at -90.3%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 2.54 indicates the company holds enough short-term assets to cover its near-term obligations.
Cue Health Inc. (HLTH) Valuation Context
Valued at $6.90M, HLTH is classified as a micro-cap stock. Relative to its peer group, HLTH's quantitative score of 44/100 is roughly in line with the peer average of 49/100.
HLTH Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Cue Health's recent insider buying suggests confidence from within, hinting at potential future growth or value appreciation.
- The community seems to be buzzing about potential partnerships or expansions, indicating positive market perception of Cue Health's strategic moves.
- Bullish community views highlight the company's innovative approach to healthcare technology, suggesting a strong belief in its long-term potential.
- Recent market developments point towards increased demand for at-home diagnostics, potentially benefiting Cue Health's product offerings.
Bear Case
- Recent insider selling, while not always negative, could signal concerns about short-term performance or market conditions affecting Cue Health.
- Bearish community views express worries about increasing competition in the at-home diagnostics market, potentially impacting Cue Health's market share.
- Community sentiment reveals concerns about the company's profitability and ability to scale production efficiently to meet growing demand.
- Market perception suggests potential regulatory hurdles or changes in healthcare policies that could negatively impact Cue Health's business model.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
HLTH Latest News
No recent news available for HLTH.
HLTH Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HLTH.
Price Targets
Wall Street price target analysis for HLTH.
HLTH MoonshotScore
What does this score mean?
The MoonshotScore rates HLTH 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Clint Sever
CEO
Clint Sever serves as the CEO of Cue Health Inc. His background includes experience in technology and healthcare, with a focus on developing and commercializing innovative diagnostic solutions. He has been instrumental in guiding Cue Health through its growth phase, including the development and launch of the Cue Integrated Care platform. His expertise spans product development, regulatory affairs, and market strategy.
Track Record: Under Clint Sever's leadership, Cue Health has secured FDA authorization for its COVID-19 test and expanded its platform to address other diagnostic needs. He has overseen the company's growth in revenue and market presence, as well as its efforts to establish strategic partnerships with healthcare providers and payers. Key milestones include the commercialization of the Cue Health Monitoring System and the development of the Cue Data and Innovation Layer.
Common Questions About HLTH (Healthcare)
What does the AI Score mean for HLTH?
HLTH holds an AI Score of 44/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Cue Health Inc. develops and commercializes diagnostic platforms for various healthcare needs. The company's integrated care platform aims to provide rapid and accurate diagnostic information …
What does Cue Health Inc. do?
Cue Health Inc. is a healthcare technology company focused on developing and commercializing its Cue Integrated Care platform. This platform provides rapid, point-of-care diagnostic testing solutions for individuals, enterprises, healthcare providers, and public health agencies. The Cue platform consists of a portable reader, single-use test cartridges, and a cloud-based data and analytics system.
What are the main risks for HLTH?
Cue Health Inc. faces several key risks, including intense competition in the point-of-care diagnostics market, regulatory hurdles and delays in obtaining approvals for new tests, and financial instability due to negative profit and gross margins. The company's success depends on its ability to innovate, commercialize new diagnostic tests, and achieve profitability.
What are the key factors to evaluate for HLTH?
Cue Health Inc. (HLTH) holds an AI score of 44/100 (low). Not financial advice.
How frequently does HLTH data refresh on this page?
HLTH's price was last updated on Jul 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven HLTH's recent stock price performance?
Cue Health Inc. (HLTH) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Integrated platform with hardware and software components. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider HLTH overvalued or undervalued right now?
Cue Health Inc. (HLTH) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research HLTH before investing?
Before investing in Cue Health Inc. (HLTH), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding HLTH to a portfolio?
Key strength of Cue Health Inc. (HLTH): Integrated platform with hardware and software components. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the most recent available information.
- The analysis is based on publicly available information and management commentary.
- Future performance is subject to various risks and uncertainties.